These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 35082323)
1. Network controllability solutions for computational drug repurposing using genetic algorithms. Popescu VB; Kanhaiya K; Năstac DI; Czeizler E; Petre I Sci Rep; 2022 Jan; 12(1):1437. PubMed ID: 35082323 [TBL] [Abstract][Full Text] [Related]
2. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma. Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274 [TBL] [Abstract][Full Text] [Related]
3. Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities. Di J; Zheng B; Kong Q; Jiang Y; Liu S; Yang Y; Han X; Sheng Y; Zhang Y; Cheng L; Han J Mol Oncol; 2019 Oct; 13(10):2259-2277. PubMed ID: 31408580 [TBL] [Abstract][Full Text] [Related]
4. MNBDR: A Module Network Based Method for Drug Repositioning. Chen HG; Zhou XH Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375395 [TBL] [Abstract][Full Text] [Related]
5. Cancer network activity associated with therapeutic response and synergism. Serra-Musach J; Mateo F; Capdevila-Busquets E; de Garibay GR; Zhang X; Guha R; Thomas CJ; Grueso J; Villanueva A; Jaeger S; Heyn H; Vizoso M; Pérez H; Cordero A; Gonzalez-Suarez E; Esteller M; Moreno-Bueno G; Tjärnberg A; Lázaro C; Serra V; Arribas J; Benson M; Gustafsson M; Ferrer M; Aloy P; Pujana MÀ Genome Med; 2016 Aug; 8(1):88. PubMed ID: 27553366 [TBL] [Abstract][Full Text] [Related]
6. Drug repurposing improves disease targeting 11-fold and can be augmented by network module targeting, applied to COVID-19. Rivero-García I; Castresana-Aguirre M; Guglielmo L; Guala D; Sonnhammer ELL Sci Rep; 2021 Oct; 11(1):20687. PubMed ID: 34667255 [TBL] [Abstract][Full Text] [Related]
7. A genome-wide positioning systems network algorithm for in silico drug repurposing. Cheng F; Lu W; Liu C; Fang J; Hou Y; Handy DE; Wang R; Zhao Y; Yang Y; Huang J; Hill DE; Vidal M; Eng C; Loscalzo J Nat Commun; 2019 Aug; 10(1):3476. PubMed ID: 31375661 [TBL] [Abstract][Full Text] [Related]
8. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212 [TBL] [Abstract][Full Text] [Related]
9. Optimal control nodes in disease-perturbed networks as targets for combination therapy. Hu Y; Chen CH; Ding YY; Wen X; Wang B; Gao L; Tan K Nat Commun; 2019 May; 10(1):2180. PubMed ID: 31097707 [TBL] [Abstract][Full Text] [Related]
10. Network-Based Drug Repositioning: Approaches, Resources, and Research Directions. Alaimo S; Pulvirenti A Methods Mol Biol; 2019; 1903():97-113. PubMed ID: 30547438 [TBL] [Abstract][Full Text] [Related]
11. Predicting Potential Drugs for Breast Cancer based on miRNA and Tissue Specificity. Yu L; Zhao J; Gao L Int J Biol Sci; 2018; 14(8):971-982. PubMed ID: 29989066 [TBL] [Abstract][Full Text] [Related]
12. Network topology measures for identifying disease-gene association in breast cancer. Ramadan E; Alinsaif S; Hassan MR BMC Bioinformatics; 2016 Jul; 17 Suppl 7(Suppl 7):274. PubMed ID: 27454166 [TBL] [Abstract][Full Text] [Related]
13. Integrative network analysis identifies potential targets and drugs for ovarian cancer. Zhang T; Zhang L; Li F BMC Med Genomics; 2020 Sep; 13(Suppl 9):132. PubMed ID: 32958005 [TBL] [Abstract][Full Text] [Related]
14. Computationally repurposing drugs for breast cancer subtypes using a network-based approach. Firoozbakht F; Rezaeian I; Rueda L; Ngom A BMC Bioinformatics; 2022 Apr; 23(1):143. PubMed ID: 35443626 [TBL] [Abstract][Full Text] [Related]
15. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing. Das AB BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131 [TBL] [Abstract][Full Text] [Related]
16. Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk. Yu L; Su R; Wang B; Zhang L; Zou Y; Zhang J; Gao L IEEE/ACM Trans Comput Biol Bioinform; 2017; 14(4):966-977. PubMed ID: 27076463 [TBL] [Abstract][Full Text] [Related]
17. A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Vizeacoumar FJ; Arnold R; Vizeacoumar FS; Chandrashekhar M; Buzina A; Young JT; Kwan JH; Sayad A; Mero P; Lawo S; Tanaka H; Brown KR; Baryshnikova A; Mak AB; Fedyshyn Y; Wang Y; Brito GC; Kasimer D; Makhnevych T; Ketela T; Datti A; Babu M; Emili A; Pelletier L; Wrana J; Wainberg Z; Kim PM; Rottapel R; O'Brien CA; Andrews B; Boone C; Moffat J Mol Syst Biol; 2013 Oct; 9():696. PubMed ID: 24104479 [TBL] [Abstract][Full Text] [Related]
18. Integration of genetic variants and gene network for drug repurposing in colorectal cancer. Irham LM; Wong HS; Chou WH; Adikusuma W; Mugiyanto E; Huang WC; Chang WC Pharmacol Res; 2020 Nov; 161():105203. PubMed ID: 32950641 [TBL] [Abstract][Full Text] [Related]
19. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Alvarez MJ; Shen Y; Giorgi FM; Lachmann A; Ding BB; Ye BH; Califano A Nat Genet; 2016 Aug; 48(8):838-47. PubMed ID: 27322546 [TBL] [Abstract][Full Text] [Related]
20. A computational method for drug repositioning using publicly available gene expression data. Shabana KM; Abdul Nazeer KA; Pradhan M; Palakal M BMC Bioinformatics; 2015; 16 Suppl 17(Suppl 17):S5. PubMed ID: 26679199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]